Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

A Phase 3 Trial of BL-M14D1 and Atezolizumab vs Standard Therapy in First‑Line Extensive‑Stage Small Cell Lung Cancer Patients

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial looks at adults with newly diagnosed extensive‑stage Small Cell Lung Cancer, a fast‑growing lung cancer that has spread beyond the lung. The study compares a new drug combination, the experimental medicine BL-M14D1 given together with atezolizumab, to the usual treatment that includes platinum etoposide chemotherapy and atezolizumab, sometimes with lurbinectedin. The purpose of the study is to see whether the new combination can keep the disease from getting worse for a longer time than the standard approach.

This is a phase 3 randomized controlled trial, meaning a large study where participants are randomly placed into one of the two treatment groups and the results are compared. The trial is open‑label, so both the doctors and the participants know which treatment is being given. Patients receive the assigned infusion every few weeks for several cycles, followed by regular clinic visits where doctors check for side effects and look for any signs that the cancer is growing. The follow‑up continues for a period of time after treatment ends to monitor health outcomes.

The main way the study measures benefit is by looking at progression‑free survival, which is the length of time from the start of treatment until the cancer shows growth or the patient dies, whichever happens first. A secondary measure is overall survival, which simply records the time from the start of treatment until death from any cause. Tumor changes are evaluated using the RECIST criteria, a standard set of rules that help doctors decide whether the cancer has grown, stayed the same, or shrunk. These outcomes help determine which treatment approach may be more effective for patients with this disease.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Screening and Baseline Assessments

    After you join the study, you will undergo screening tests to confirm that you meet the eligibility criteria for the trial.

    Screening includes blood tests, imaging studies such as a CT scan, and a review of your medical history to document the extent of small cell lung cancer.

  2. Step 2

    Randomization

    Once eligibility is confirmed, you will be randomly assigned to one of two treatment groups.

    The assignment is done by a computer system, so you will not know which group you are placed in.

  3. Step 3

    First Treatment Cycle

    If you are assigned to the investigational group, you will receive an intravenous infusion of atezolizumab at a dose of 1200 mg and an infusion of BL‑M14D1 according to the study protocol.

    If you are assigned to the standard‑of‑care group, you will receive the usual chemotherapy regimen (platinum plus etoposide) together with atezolizumab at the same dose.

    Infusions are administered in a clinic or hospital setting over a period of several hours, and you will be observed for any immediate reactions.

  4. Step 4

    Ongoing Treatment Cycles

    You will continue to receive the assigned infusions on a regular schedule, typically every three weeks, as outlined in the study plan.

    Before each infusion, blood work will be repeated to check organ function and to ensure it is safe to proceed.

    The number of cycles is determined by the study protocol and will continue until disease progression, unacceptable side effects, or completion of the planned treatment period.

  5. Step 5

    Imaging Assessments

    Periodically, you will undergo imaging scans (for example, CT scans) to evaluate how the cancer is responding to treatment.

    These scans are interpreted using standard criteria called RECIST, which measure changes in tumor size in a consistent way.

  6. Step 6

    Safety Monitoring

    Throughout the trial, you will be asked to report any side effects or new symptoms.

    Regular clinical visits will include physical examinations and laboratory tests to monitor your safety.

  7. Step 7

    End of Treatment

    Treatment will stop if the disease shows progression, if side effects become too severe, or after the maximum number of cycles defined in the protocol has been completed.

    You will be informed of the reason for stopping treatment.

  8. Step 8

    Follow‑Up Phase

    After treatment ends, you will continue to be followed by the study team for survival outcomes, including overall survival and progression‑free survival.

    Follow‑up visits may include periodic scans and blood tests, typically every few months, to track your health status.

Who can join the trial?

5 criteria

  • Be at least 18 years old.
  • Have a confirmed diagnosis of extensive-stage Small Cell Lung Cancer that has not been treated before (the cancer has spread widely and you have not received therapy for it yet).
  • Have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (this means you are fully active or able to do light work).
  • Have measurable disease (the cancer can be seen and measured on scans or other tests).
  • Have adequate organ function (your heart, liver, kidneys, and blood are working well enough for the study).

Who cannot join the trial?

4 criteria

  • You have already received systemic (whole‑body) treatment for extensive‑stage small cell lung cancer.
  • You currently have an autoimmune disease (a condition where the immune system mistakenly attacks the body’s own tissues, such as rheumatoid arthritis or lupus).
  • You have serious cardiovascular disease (significant heart or blood‑vessel problems, like a recent heart attack, severe heart failure, or uncontrolled high blood pressure).
  • You have an active infection (any infection that is currently present and requires treatment, such as pneumonia, a urinary tract infection, or similar).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Atezolizumab

    is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. In this trial it is used as part of the standard treatment and also combined with the experimental drug to see if it improves outcomes for patients with extensive‑stage small cell lung cancer.

  • BL-M14D1

    is an investigational medication being tested for the first time in this study. It is given through an IV infusion and is being evaluated to determine whether it can work together with atezolizumab to slow the growth of the cancer compared with the usual treatments.

  • Platinum etoposide chemotherapy

    is a standard combination of two chemotherapy drugs that are given by IV. The platinum component (often carboplatin or cisplatin) and etoposide work together to kill rapidly growing cancer cells. This regimen is part of the usual care for extensive‑stage small cell lung cancer and serves as a comparison for the new treatment approach.

  • Lurbinectedin

    is a newer chemotherapy drug that can be added to the standard regimen of platinum, etoposide, and atezolizumab. It works by interfering with the DNA of cancer cells, helping to stop them from growing. In this trial some patients receive it to see if it adds any benefit to the standard therapy.

What is already known about the treatment

  • Tecentriq

    Tecentriq is given as an intravenous infusion of a sterile solution that is mixed and delivered through a vein. It is an approved drug that is listed in medical literature as a treatment for several cancers, including small cell lung cancer. The medicine works by blocking a protein called PD‑L1, which helps the body’s immune system recognize and fight cancer cells. It belongs to the class of immune checkpoint inhibitors, a type of monoclonal antibody therapy.

  • BL-M14D1

    BL-M14D1 is administered as an intravenous infusion of a clear solution, similar to standard cancer medicines given through a vein. It is an investigational product that is still being studied and has not yet received regulatory approval. The drug is thought to activate the immune system to target cancer cells, although its exact molecular action is still under research. It is classified as an experimental biologic agent being tested for use in lung cancer.

Investigated diseases

  • Small Cell Lung Cancer

    A fast‑growing cancer that begins in the neuroendocrine cells of the bronchi, tends to invade nearby structures, commonly spreads through blood and lymph to distant organs, and may develop new tumor sites as the disease advances.

  • Lung Cancer

    A collective term for malignant tumors that arise from cells lining the airways or deeper lung tissue, can start as a small lesion that enlarges locally, and may later extend into surrounding tissues and travel to other parts of the body.

Trial detailsLast updated 22 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2026-526781-24-00Protocol codeBL-M14D1-LC-301Estimated enrolment354 patientsSponsorSystimmune Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.